Further Information on Immune Thrombotic Thrombocytopenia Following SARS-CoV-2 Vaccination

Almost all patients with vaccine-induced immune thrombotic thrombocytopenia had anti–platelet factor 4 antibodies, as in rarely reported autoimmune heparin-induced thrombocytopenia.

Recent reports have described a syndrome involving thrombosis with thrombocytopenia and coagulopathy following administration of the AstraZeneca vaccine against SARS-CoV-2 (NEJM JW Infect Dis May 2021 and N Engl J Med 2021 Apr 9; [e-pub]); similar events have been reported in several patients who received the Johnson & Johnson vaccine in the U.S. To better understand the mechanism of this vaccine-induced immune thrombotic thrombocytopenia (VITT), investigators studied 23 patients (22 with thrombosis and thrombocytopenia; 1 with thrombocytopenia and a marked increase in D-dimer).

Key findings included:

The patients (median age, 46; 61% women) were vaccinated a median of 12 days prior to presentation; only one had a prior history of deep venous…

Reviewing Author

Brady Stein, MD, MHS

Disclosures

Leadership Positions in Professional SocietiesAmerican Society of Hematology (Senior Editor, ASH Self-Assessment Program; guideline development)

Brady Stein, MD, MHS

Disclosures

Leadership Positions in Professional SocietiesAmerican Society of Hematology (Senior Editor, ASH Self-Assessment Program; guideline development)

Further Information on Immune Thrombotic Thrombocytopenia Following SARS-CoV-2 Vaccination

Topics

Reviewing Author